Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) Director Barbara Weber sold 5,200 shares of the company’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $48.02, for a total transaction of $249,704.00. Following the completion of the transaction, the director now directly owns 13,065 shares in the company, valued at approximately $627,381.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Revolution Medicines Trading Up 2.0 %
NASDAQ RVMD opened at $50.48 on Friday. The firm has a market cap of $8.43 billion, a PE ratio of -13.87 and a beta of 1.43. Revolution Medicines, Inc. has a 1-year low of $15.44 and a 1-year high of $51.00. The stock has a 50-day moving average of $44.10 and a 200-day moving average of $40.73.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The business had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.81 million. During the same period in the prior year, the firm earned ($0.92) EPS. The business’s revenue was down 73.8% on a year-over-year basis. As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -3.35 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Research Report on RVMD
Institutional Investors Weigh In On Revolution Medicines
Large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in shares of Revolution Medicines by 55.8% during the third quarter. GAMMA Investing LLC now owns 620 shares of the company’s stock worth $28,000 after purchasing an additional 222 shares during the period. Headlands Technologies LLC increased its stake in shares of Revolution Medicines by 140.9% during the first quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock valued at $49,000 after buying an additional 885 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of Revolution Medicines during the first quarter valued at approximately $104,000. EntryPoint Capital LLC bought a new position in shares of Revolution Medicines during the first quarter valued at approximately $107,000. Finally, Nisa Investment Advisors LLC boosted its holdings in Revolution Medicines by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock valued at $131,000 after acquiring an additional 320 shares in the last quarter. Institutional investors own 94.34% of the company’s stock.
Revolution Medicines Company Profile
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Further Reading
- Five stocks we like better than Revolution Medicines
- What is the Shanghai Stock Exchange Composite Index?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- When to Sell a Stock for Profit or Loss
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.